Sex and dosing-time dependencies in irinotecan-induced circadian disruption

Chronobiology International

Volumn 28, Issue 5, 2011, Pages 458-470

  Ahowesso, Constance ^a,b   Li, Xiao Mei ^a,b   Zampera, Sinisa ^c   Peteri Brunbäck, Brigitta ^d   Dulong, Sandrine ^a,b   Beau, Jacques ^a,b   Hossard, Virginie ^a,b   Filipski, Elisabeth ^a,b   Delaunay, Franck ^d   Claustrat, Bruno ^e   Lévi, Francis ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Helios Biosciences   (France)

^d UNIVERSITÉ CÔTE D'AZUR   (France)

^e STEM CELL AND BRAIN RESEARCH INSTITUTE   (France)

Author keywords

Body temperature; Chronotherapy; Circadian clocks; Clock genes; Irinotecan; Personalized medicine; Rest activity cycle; Sex

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CORTICOSTERONE; DRUG DERIVATIVE; IRINOTECAN; TRANSCRIPTION FACTOR CLOCK;

ANIMAL; ARTICLE; BLOOD; BODY TEMPERATURE; CIRCADIAN RHYTHM; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LIVER; MALE; METABOLISM; MOTOR ACTIVITY; MOUSE; PHYSIOLOGY; SEXUAL DEVELOPMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY TEMPERATURE; CAMPTOTHECIN; CIRCADIAN RHYTHM; CLOCK PROTEINS; CORTICOSTERONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION; LIVER; MALE; MICE; MOTOR ACTIVITY; SEX CHARACTERISTICS;

MUS;

EID: 79959968868     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2011.569043     Document Type: Article

References (58)

1. Ahabrach H, Piedrafita B, Ayad A, El Mlili N, Errami M, Felipo V, Llan-sola M. (2010). Chronic hyperammonemia alters the circadian rhythms of corticosteroid hormone levels and of motor activity in rats. J. Neurosci. Res. 88: 1605-1614.
2. Ahowesso C, Li XM, Levi F. (2009). Preclinical model for the personalization of cancer chronotherapeutics. Presented at the XI Congress of the European Biological Rhythms Society, August 22-28, Strasbourg.
3. Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, Filipski E, Tinari N, Delaunay F, Iacobelli S, Lévi F. (2010). Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol. Lett. 192:395-401.
4. Akagi T, Fukagawa T, Kage Y, To H, Matsunaga N, Koyanagi S, Uchida A, Fujii A, Iba H, Ikemura T, Aramaki H, Higuchi S, Ohdo S. (2009). Role of glucocorticoid receptor in the regulation of cellular sensitivity to irinotecan hydrochloride. J. Pharmacol. Sci. 109:265-274.
5. Altinok A, Lévi F, Goldbeter A. (2009). Identifying mechanisms of chronotolerance and chronoefficacy for the anticancer drugs 5-fluorouracil and oxaliplatin by computational modeling. Eur. J. Pharmaceut. Sci. 36:20-38.
6. Bingham C, Arbogast B, Guillaume GC, Lee JK, Halberg F. (1982). Inferential statistical methods for estimating and comparing cosinor parameters. Chronobiologia 9:397-439. (Pubitemid 13122417)
7. Bouzahzah B, Pavier D, Barbason H. (1998). The role of corticoids, adrenalectomy, phenobarbital and pentobarbital in the promotion of DEN-hepatocarcinogenesis. In Vivo 12:411-419. (Pubitemid 28382922)
8. Bowen JM, Gibson RJ, Cummins AG, Tyskin A, Keefe DM. (2007). Iri-notecan changes gene expression in the small intestine of the rat with breast cancer. Cancer Chemother. Pharmacol. 59:337-348. (Pubitemid 46025521)
9. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT. (2008). Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J. Clin. Oncol. 26:2690-2698.
10. Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 105:9053-9058.
11. Cecchin E, Innocenti F, D'Andrea M. (2009). Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol. 27:2419-2421.
12. Chomczynski P, Sacchi N. (2006). The single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction: twenty-something years on. Nat. Protocol. 1:581-585.
13. Claudel T, Cretenet G, Saumet A, Gachon F. (2007). Crosstalk between xenobiotics metabolism and circadian clock. FEBS Lett. 581:3626-3633. (Pubitemid 47080999)
14. Duguay D, Cermakian N. (2009). The crosstalk between physiology and circadian clock proteins. Chronobiol. Int. 26:1479-1513.
15. Filipski E, Lévi F. (2009). Circadian disruption in experimental cancer processes. Integr. Cancer Ther. 8:298-302.
16. Filipski E, King VM, Li XM, Granda TG, Mormont MC, Liu XH, Claus-trat B, Hastings MH, Lévi F. (2002). Host circadian clock as a control point in tumor progression. J. Natl. Cancer Inst. 94:690-697. (Pubitemid 34552490)
17. Filipski E, Lemaigre G, Liu X.H, Méry-Mignard D, Mahjoubi M, Lévi F. (2004). Circadian rhythm of irinotecan tolerability in mice. Chron-obiol. Int. 21:3-30.
18. Filipski E, Innominato PF, Wu MW, Li XM, Iacobelli S, Xian LJ, Lévi F. (2005). Effects of light and food schedules on liver and tumor molecular clocks in mice. J. Natl. Cancer Inst. 97:507-517. (Pubitemid 40590432)
19. Filipski E, Subramanian P, Carrière J, Guettier C, Barbason H, Lévi F. (2009). Circadian disruption accelerates liver carcinogenesis in mice. Mutat. Res. 680:95-105.
20. Fu L, Lee CC. (2003). The circadian clock: pacemaker and tumour suppressor. Nat. Rev. Cancer 3:350-361. (Pubitemid 37328855)
21. Fu L, Pelicano H, Liu J, Huang P, Lee CC. (2002). The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41-50
22. Grechez-Cassiau A, Panda S, Lacoche S, Teboul M, Azmi S, Laudet V, Hogenesch JB, Taneja R, Delaunay F. (2004). The transcriptional repressor STRA13 regulates a subset of peripheral circadian outputs. J. Biol. Chem. 279:1141-50. (Pubitemid 38082636)
23. Granda TG, Lévi F. (2002). Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol. Int. 19:21-41. (Pubitemid 34310818)
24. Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F. (2002). Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br. J. Cancer 86:999-1005. (Pubitemid 34271040)
25. Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, Lévi F. (2005). Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB 19:304-306. (Pubitemid 40189290)
26. Hastings MH, Reddy AB, Maywood ES. (2003). A clockwork web. Circadian timing in brain and periphery, in health and disease. Nat. Rev. Neurosci. 4:649-661. (Pubitemid 37280160)
27. Haus E, Halberg F. (1980). Endocrine rhythms. In Scheving LE, Halberg F (eds.). Chronobiology: principles and applications to shifts in schedules. Alphen an den Rijn: Sijthoff & Noordhoff, 137-188.
28. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, Wenz F, Hochhaus A, Post S, Willeke F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). (2009). Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 20:519-524.
29. Innominato PF, Focan C, Gorlia T, Moreau T, Garufi C, Waterhouse J, Giacchetti S, Coudert B, Iacobelli S, Genet D, Tampellini M, Chollet P, Lentz MA, Mormont MC, LéviF, Bjarnason GA. (2009). Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res. 69:4700-4707.
30. Ishida A, Mutoh T, Ueyama T, Bando H, Masubuchi S, Nakahara D, Tsujimoto G, Okamura H. (2005). Light activates the adrenal gland: timing of gene expression and glucocorticoid release. Cell Metab. 2:297-307.
31. Iurisci I, Filipski E, Reinhardt J, Bach S, Gianella-Borradori A, Iacobelli S, Meijer L, Lévi F. (2006). Improved tumor control through circa-dian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Cancer Res. 66:10720-10728. (Pubitemid 44876967)
32. Iurisci I, Rich T, Lévi F, Innominato PF, Tinari N, Irtelli L, De Tursi M, Grassadonia A, Iacobelli S. (2007). Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer. J. Clin. Oncol. 25:17-19.
33. Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Lévi F. (2009). Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol. Int. 26:1169-1188.
34. Kennaway DJ, Owens JA, Voultsios A, Varcoe TJ. (2006). Functional central rhythmicity and light entrainment, but not liver and muscle rhythmicity, are Clock independent. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291:R1172-R1180. (Pubitemid 44498460)
35. Kiessling S, Eichele G, Oster H. (2010). Adrenal glucocorticoids have a key role in circadian resynchronization in a mouse model of jet lag. J. Clin. Invest. 120:2600-2609.
36. Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentherou-dakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G. (2009). Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy. BMC Cancer 9:339.
37. Kuramoto Y, Hata K, Koyanagi S, Ohdo S, Shimeno H, Soeda S. (2006). Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones. Biochem. Pharmacol. 71:1155-1161. (Pubitemid 43357896)
38. Kweekel D, Guchelaar HJ, Gelderblom H. (2008). Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat. Rev. 34:656-669.
39. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. (2010). Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One 5:e10995.
40. Lehman MN, Silver R, Gladstone WR, Kahn RM, Gibson M, Bittman EL. (1987). Circadian rhythmicity restored by neural transplant. Immunocytochemical characterization of the graft and its integration with the host brain. J. Neurosci. 7:1626-1638. (Pubitemid 17119785)
41. Lévi F, Schibler U. (2007). Circadian rhythms: mechanisms and therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 47:593-628.
42. Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. (2010). Circadian timing in cancer treatments. Annu. Rev. Pharmacol. Toxicol. 50:377-421.
43. Li XM, Lévi F. (2007). Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice. J. Biol. Rhythms 22:159-166. (Pubitemid 46568651)
44. Li XM, Vincenti M, Lévi F. (2002). Pharmacological effects of vinorelbine on body temperature and locomotor activity circadian rhythms in mice. Chronobiol. Int. 19:43-55. (Pubitemid 34310819)
45. Li XM, Delaunay F, Dulong S, Claustrat B, Zampera S, Fujii Y, Teboul M, Beau J, Lévi F. (2010). Cancer inhibition through circadian reprogramming of tumor transcriptome with meal timing. Cancer Res. 70:3351-3360.
46. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182-2194. (Pubitemid 32751614)
47. Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. (2005). In vitro and in vivo irino-tecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol. Cancer Ther. 4:885-900. (Pubitemid 40909071)
48. th, 2001, Sans Francisco, California, USA, abstr. 2200.
49. Ohdo S, Koyanagi S, Suyama H, Higuchi S, Aramaki H. (2001). Changing the dosing schedule minimizes the disruptive effects of interferon on clock function. Nat. Med. 7:356-360. (Pubitemid 32224353)
50. Oklejewicz M, Destici E, Tamanini F, Hut RA, Janssens R, van der Horst GT. (2008). Phase resetting of the mammalian circadian clock by DNA damage. Curr. Biol. 18:286-291.
51. Pommier Y, Weinstein JN, Aladjem MI, Kohn KW. (2006). Chk2 molecular interaction map and rationale for Chk2 inhibitors. Clin. Cancer Res. 12:2657-2661.
52. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911-1929.
53. Rothenberg ML, Meropol NJ, Poplin EA, van Cutsem E, Wadler S. (2001). Mortality associated with irinotecan plus bolus fluoroura-cil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:3801-3807. (Pubitemid 32880058)
54. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. (2000). Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 92:994-1000. (Pubitemid 30469965)
55. Souza V, Dong YB, Zhou HS, Zacharias W, McMasters KM. (2005). W-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling. J. Transl. Med. 23:3-44.
56. Takahashi JS, Hong HK, Ko CH, McDearmon EL. (2008). The genetics of mammalian circadian order and disorder: implications for physiology and disease. Nat. Rev. Genet. 9:764-75.
57. Takemura H, Rao VA, Sordet O, Furuta T, Miao ZH, Meng L, Zhang H, Pommier Y. (2006). Defective Mre11-dependent activation of Chk2 by ataxia telangiectasia mutated in colorectal carcinoma cells in response to replication-dependent DNA double strand breaks. J. Biol Chem. 281:30814-30823. (Pubitemid 44582136)
58. Yang F, Nakajima Y, Kumagai M, Ohmiya Y, Ikeda M. (2009). The molecular mechanism regulating the autonomous circadian expression of topoisomerase I in NIH3T3 cells. Biochem. Biophys. Res. Commun. 380:22-27.